Luteolin vs Quercetin
One hydroxyl apart — a flavone and a flavonol — and routinely treated as the same thing. Their human records are the part that does not match.
Short answer
The evidence gap decides this one. Quercetin has human clinical data behind it, while luteolin has only preclinical or minimal evidence, resting mostly on animal or lab work. Someone focused on senolytic use, blood pressure and immunity has trial data to go on with quercetin; luteolin, marketed for mast-cell stabilization, brain fog and neuroinflammation, is still an early-research option.
Luteolin
3',4',5,7-tetrahydroxyflavone, cynaroside
A genuinely strong mast-cell and microglial mechanism whose entire human record is combination products — and the one placebo-controlled test of luteolin alone was negative.
Full Luteolin evidence reviewQuercetin
Modest, real blood-pressure benefit; its senolytic fame belongs to the dasatinib+quercetin combo in tiny pilots, not quercetin alone.
Full Quercetin evidence reviewLuteolin vs Quercetin: head to head
- FDA status / approved use
Luteolin
Sold as a dietary supplement; no FDA approval for any indicationQuercetin
Sold as a supplement; also a normal part of the diet- Marketed for
Luteolin
Mast-cell stabilization, brain fog / neuroinflammation, allergy, senolyticQuercetin
Senolytic, blood pressure, immunity- Outcome areas
Luteolin
Immune function / inflammation; Cognitive function / memory; Cellular senescenceQuercetin
Cardiovascular; Cellular senescence; Immune function / inflammation- Evidence grade
Luteolin
Preclinical / minimalQuercetin
Clinical data- How it works
Luteolin
Inhibits mast-cell release of histamine and other mediators in lab studiesQuercetin
Dietary flavonoid; acts as a senolytic only combined with dasatinib- Route and dosing
Luteolin
Oral capsule, typically 100–300 mg dailyQuercetin
Supplement capsule; blood pressure effect strongest at ≥500 mg/day- Headline human result
Luteolin
No benefit over placebo at either dose in a crossover screening trial of 21 Gulf War Illness veteransQuercetin
About 3.0 mmHg lower systolic and 2.6 mmHg lower diastolic blood pressure in a meta-analysis of 7 RCTs- Strongest evidence
Luteolin
Placebo-controlled crossover screen, IJERPH 2021. Little or no controlled human outcome data for the marketed useLuteolin evidence reviewPubMed 33802381Quercetin
BP meta-analysis, JAHA 2016Quercetin evidence reviewPubMed 27405810- Key safety signal
Luteolin
No long-term human safety data at supplement doses; inhibits CYP1A2 and CYP2C8 in lab studiesQuercetin
Well tolerated; high doses can cause mild GI effects; drug-interaction caution applies- How it is obtained
Luteolin
Over the counter as a dietary supplementQuercetin
Over the counter as a dietary supplement
| Luteolin | Quercetin | |
|---|---|---|
| FDA status / approved use | Sold as a dietary supplement; no FDA approval for any indication | Sold as a supplement; also a normal part of the diet |
| Marketed for | Mast-cell stabilization, brain fog / neuroinflammation, allergy, senolytic | Senolytic, blood pressure, immunity |
| Outcome areas | Immune function / inflammation; Cognitive function / memory; Cellular senescence | Cardiovascular; Cellular senescence; Immune function / inflammation |
| Evidence grade | Preclinical / minimal | Clinical data |
| How it works | Inhibits mast-cell release of histamine and other mediators in lab studies | Dietary flavonoid; acts as a senolytic only combined with dasatinib |
| Route and dosing | Oral capsule, typically 100–300 mg daily | Supplement capsule; blood pressure effect strongest at ≥500 mg/day |
| Headline human result | No benefit over placebo at either dose in a crossover screening trial of 21 Gulf War Illness veterans | About 3.0 mmHg lower systolic and 2.6 mmHg lower diastolic blood pressure in a meta-analysis of 7 RCTs |
| Strongest evidence | Placebo-controlled crossover screen, IJERPH 2021. Little or no controlled human outcome data for the marketed useLuteolin evidence reviewPubMed 33802381 | BP meta-analysis, JAHA 2016Quercetin evidence reviewPubMed 27405810 |
| Key safety signal | No long-term human safety data at supplement doses; inhibits CYP1A2 and CYP2C8 in lab studies | Well tolerated; high doses can cause mild GI effects; drug-interaction caution applies |
| How it is obtained | Over the counter as a dietary supplement | Over the counter as a dietary supplement |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
- Preclinical / minimal:
- Evidence is largely animal, in-vitro, or anecdotal. Little or no controlled human outcome data for the marketed use.
Our verdict
Luteolin is a flavone and quercetin a flavonol; structurally luteolin is quercetin with one hydroxyl removed, which is why the two get flattened together and precisely why they should not be. Quercetin has one genuinely supported human benefit of its own: a meta-analysis of seven randomized trials in 587 patients found systolic blood pressure fell about 3.0 mmHg and diastolic about 2.6 mmHg, strongest at 500 mg a day or more. Luteolin has no equivalent, because nearly every human trial gave people a blend — most often 700 mg of palmitoylethanolamide to 70 mg of luteolin, a ten-to-one ratio in favor of the other ingredient — and the one published placebo-controlled test of luteolin by itself was negative at both doses. Both are oversold as senolytics: quercetin's reputation there belongs to the dasatinib-plus-quercetin combination tested in open-label pilots of 9 to 14 people, and luteolin was weak even in the cell screen.
Luteolin fits if
Luteolin is the closer fit for someone whose real interest is mast-cell or neuroinflammatory biology, and who understands they are reading a mechanism rather than acting on a human result that does not yet exist.
Quercetin fits if
Quercetin is the better-evidenced of the two, and only narrowly — a low-risk dietary flavonoid taken at 500 mg or more for modest blood-pressure support, not for clearing senescent cells.
Luteolin vs Quercetin: common questions
- Is either luteolin or quercetin FDA-approved?
- No. Luteolin is sold as a dietary supplement; no FDA approval for any indication. Quercetin is sold as a supplement; also a normal part of the diet.
- Which has stronger human evidence, luteolin or quercetin?
- Quercetin. It has human clinical data (key source: BP meta-analysis, JAHA 2016), while luteolin has only preclinical or minimal evidence (key source: Placebo-controlled crossover screen, IJERPH 2021).
- What are the main safety concerns with luteolin and quercetin?
- Luteolin has no long-term human safety data at supplement doses; inhibits CYP1A2 and CYP2C8 in lab studies. Quercetin is well tolerated; high doses can cause mild GI effects; drug-interaction caution applies.
Key studies behind each
Luteolin
- Shi M, Chen Z, Gong H, Peng Z, Sun Q, Luo K, Wu B, Wen C, Lin W. (2024). Luteolin, a flavone ingredient: Anticancer mechanisms, combined medication strategy, pharmacokinetics, clinical trials, and pharmaceutical researches. Phytother Res. PubMed 38088265
- Sampson L, Rimm E, Hollman PC, de Vries JH, Katan MB. (2002). Flavonol and flavone intakes in US health professionals. J Am Diet Assoc. PubMed 12396158
- Shimoi K, Okada H, Furugori M, Goda T, Takase S, Suzuki M, Hara Y, Yamamoto H, Kinae N. (1998). Intestinal absorption of luteolin and luteolin 7-O-beta-glucoside in rats and humans. FEBS Lett. PubMed 9827549
- Tsilioni I, Theoharides TC. (2024). Luteolin Is More Potent than Cromolyn in Their Ability to Inhibit Mediator Release from Cultured Human Mast Cells. Int Arch Allergy Immunol. PubMed 38588651
Quercetin
- Serban MC, Sahebkar A, Zanchetti A, et al. (2016). Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. PubMed 27405810
- Justice JN, Nambiar AM, Tchkonia T, et al. (2019). Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. PubMed 30616998
- Hickson LJ, Langhi Prata LGP, Bobart SA, et al. (2019). Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. PubMed 31542391
- Pelletier DM, Lacerte G, Goulet ED. (2013). Effects of quercetin supplementation on endurance performance and maximal oxygen consumption: a meta-analysis. Int J Sport Nutr Exerc Metab. PubMed 22805526
The full evidence reviews
- Luteolin: an excellent mechanism, and almost no human evidence
Luteolin beats the only licensed mast-cell blocker in a dish and calms microglia in aged mice — but nearly every human trial gave people a combination product, and the one placebo-controlled test of luteolin alone was negative.
Updated August 2026
- Quercetin: one real benefit, and a reputation that outruns it
A flavonoid with modest, meta-analysis-backed blood-pressure benefit — but its 'senolytic' fame belongs to the dasatinib+quercetin combo, and its exercise and allergy claims are weak.
Updated August 2026